WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H326892
CAS#: 94739-29-4
Description: Lemildipine, also known as NB-818; NPK-1886, is a calcium channel blocker potentially for the treatment of hypertension.. Lemildipine attenuates the TGF response in SHR by dilating afferent arterioles and thereby corrects the left and downward shift of the TGF curve in SHR. In addition, the fall in FF indicates lemildipine-induced efferent arteriolar vasodilatation. Through balanced systemic and glomerular vasodilatation, lemildipine maintains the levels of Pgc and GFR in the face of reduced renal perfusion pressure.
Hodoodo Cat#: H326892
Name: Lemildipine
CAS#: 94739-29-4
Chemical Formula: C20H22Cl2N2O6
Exact Mass: 456.09
Molecular Weight: 457.304
Elemental Analysis: C, 52.53; H, 4.85; Cl, 15.50; N, 6.13; O, 20.99
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: NB-818; NB 818; NB818; NPK-1886; NPK 1886; NPK1886; Lemildipine
IUPAC/Chemical Name: 3-isopropyl 5-methyl 2-((carbamoyloxy)methyl)-4-(2,3-dichlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
InChi Key: WTOVRSWDBLIFHU-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H22Cl2N2O6/c1-9(2)30-19(26)16-13(8-29-20(23)27)24-10(3)14(18(25)28-4)15(16)11-6-5-7-12(21)17(11)22/h5-7,9,15,24H,8H2,1-4H3,(H2,23,27)
SMILES Code: O=C(C1=C(COC(N)=O)NC(C)=C(C(OC)=O)C1C2=CC=CC(Cl)=C2Cl)OC(C)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 457.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Nakayama K, Nakazawa T, Fukuta Y, Tanaka Y. Stereo-selective calcium antagonistic and binding properties of the enantiomers of lemildipine in vascular tissue of pigs and dogs. Arzneimittelforschung. 1996 Nov;46(11):1045-53. PubMed PMID: 8955863.
2: Hattori Y, Fukao M, Houzen H, Qi F, Yamada Y, Kanno M. In vitro assessment for vascular selectivity of a new dihydropyridine derivative, NB-818. Eur J Pharmacol. 1996 Apr 22;301(1-3):99-106. PubMed PMID: 8773452.
3: Yamazaki Y, Ebiike H, Achiwa K. Determination of the absolute configuration of biologically active (S)-(-)-NB 818 and its structural correlation with the stereoselectivity of the channel blocking action. Chem Pharm Bull (Tokyo). 1994 Sep;42(9):1968-70. PubMed PMID: 7954946.
4: Kamei K, Tsuchida S, Taguchi K, Nishikibe M. Effect of a new calcium entry blocker, NB-818, on delayed neuronal death in the ischemic gerbil hippocampus. Jpn J Pharmacol. 1991 Jul;56(3):279-86. PubMed PMID: 1895574.
5: Abe H, Katada K, Orita M, Nishikibe M. Effects of calcium antagonists on the erythrocyte membrane. J Pharm Pharmacol. 1991 Jan;43(1):22-6. PubMed PMID: 1676054.
6: Nagura J, Suzuki K, Shiratori K, Fukuroda T, Nishikibe M, Murayama B, Takeya K. Comparison of the cardiovascular effects of three dihydropyridine compounds. Arch Int Pharmacodyn Ther. 1989 Nov-Dec;302:174-85. PubMed PMID: 2636815.
7: Nishikibe M, Kamei K, Nagura J, Suzuki K. Effect of the newly synthetized calcium antagonist isopropyl methyl 2-carbamoyloxymethyl-6-methyl-4-(2,3-dichlorophenyl)-1,4-dihydropyridine-3,5- dicarboxylate on cerebral venous outflow in dogs. Arzneimittelforschung. 1989 Jun;39(6):678-81. PubMed PMID: 2775334.
8: Kamei K, Tsuchida S, Nishikibe M. [Effects of NB-818 on a transient bilateral common carotid arteries occlusion model in Mongolian gerbils]. Nihon Yakurigaku Zasshi. 1989 Jun;93(6):341-7. Japanese. PubMed PMID: 2737569.
9: Suzuki K, Nagura J, Shiratori K, Murayama B, Harada N, Miyano T, Takeya K. Study of the structure-activity relationships of new dihydropyridine derivatives. J Pharmacobiodyn. 1989 May;12(5):293-8. PubMed PMID: 2810018.
10: Nishikibe M, Fukuroda T, Nakajima A. Vasodilatory properties in vascular smooth muscle of the calcium antagonist NB-818 compared to nicardipine and nimodipine. Arch Int Pharmacodyn Ther. 1989 Jan-Feb;297:98-111. PubMed PMID: 2730244.
11: Takano T, Hata S. Selected ion monitoring analysis of NB-818, a new calcium entry blocker in a series of dihydropyridines, in human plasma. Biomed Environ Mass Spectrom. 1988 Dec;17(6):477-82. PubMed PMID: 3240375.
12: Nishikibe M. Effect of the calcium entry blocker NB-818 on cerebral blood flow after unilateral carotid occlusion in the Mongolian gerbil. J Pharmacol Exp Ther. 1988 Aug;246(2):719-25. PubMed PMID: 3404454.
13: Nishikibe M, Nagura J, Kamei K, Fukuroda T. Hemodynamic effects of a dihydropyridine calcium antagonist, NB-818 (NPK-1886) in anesthetized dogs. Arch Int Pharmacodyn Ther. 1988 Jan-Feb;291:7-20. PubMed PMID: 3365068.
14: Nishikibe M, Nakajima A. Effects of the calcium antagonist NB-818 on cerebral blood flow. Life Sci. 1988;43(21):1715-23. PubMed PMID: 3193855.
15: Nagura J, Murayama B, Harada N, Suzuki K, Miyano T, Yajima M, Takeya K. Cardiovascular effects of NPK-1886, a new dihydropyridine compound with calcium entry blocking activity. Jpn J Pharmacol. 1986 Mar;40(3):399-409. PubMed PMID: 3712868.
